Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 57 % of short-term debt in 2023; threshold 65 %.
-
Annual account missing NBB
Fiscal year 2024 was expected before 31 October 2024 and has not been filed.
Financials
Financial year 2023
PHOENIX Pharma Belgium from Sint-Lambrechts-Woluwe, company number BE0425353116, closed financial year 2023 with a result of € -2.7 million after tax. For that financial year PHOENIX Pharma Belgium recorded revenue of € 1.1 billion and equity of € 18.8 million. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 11, 2023.
€ 18.8 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.7 million
Profit after tax over the fiscal year.
€ 217,876
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1.8 million.
People and assets in 2023
560.1
Average over the fiscal year, from the social balance sheet.
€ 33.8 million
€ 60,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1.1 million
Of which on lease € 935,124.
Debts at end 2023
€ 1.5 million
€ 195,983 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 137.1 million
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 46 days on average.
€ 8.7 million
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to PHOENIX Pharma Belgium?
What happened at PHOENIX Pharma Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Philippe LACROIX stepped down as director. NBB
- New annual accounts for financial year 2023: loss of € 2.7 million. Source: NBB ↗
- Arnaud Berken stepped down as director. NBB
- Hubert OLIVIER stepped down as director. NBB
- Hubert OLIVIER became a director. NBB
- Philippe LACROIX became a director. NBB
- Arnaud Berken became a director. NBB
- New establishment in Gent. KBO
In short
Paid € 517,582 in corporate taxes since 2023.
Pays suppliers within 46 days on average.
A new publication or filing at PHOENIX Pharma Belgium? We notify you, reason included.
Follow PHOENIX Pharma BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by PHOENIX Belgium (100%).
Directors
According to the 2023 annual accounts
since 2021 · until 2022
since 2021 · until 2024
since 2020 · until 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Emile Vanderveldelaan 82
1200 Sint-Lambrechts-Woluwe
Hendriklei 69
2660 Antwerpen
Active since 1 April 1967
Industrieweg (B) 106
3980 Tessenderlo-Ham
Active since 1 April 1967
Chemin de la Reconversion(H-G) 15
7110 La Louvière
Active since 23 August 2005
Avenue de l'Energie 33
4432 Ans
Active since 1 November 2010
Avenue Pasteur 2
1300 Wavre
Active since 1 September 2014
Cokeriestraat 5
1850 Grimbergen
Active since 1 September 2015
Marthe Versichelenstraat 1
9052 Gent
Active since 1 October 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0425.353.116
- VAT number
- BE 0425.353.116
- Registered office
- Emile Vanderveldelaan 82, 1200 Sint-Lambrechts-Woluwe
- Names & denominations
- PHOENIX Pharma Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 1983
- Peppol
- Active · Active since 17 Dec 2024
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Vervaardiging van geneesmiddelen